Gilead Sciences, Inc. is a prominent American biopharmaceutical company headquartered in Foster City, California. Founded in 1987 by Michael L. Riordan under the name Oligogen, the company focuses on researching and developing antiviral drugs for various diseases, including HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. Gilead is particularly known for its innovative therapies such as ledipasvir/sofosbuvir and sofosbuvir, which have significantly impacted the treatment landscape for these conditions[2].

## Company Overview
- **Founded**: 1987 (as Oligogen)
- **Headquarters**: Foster City, California
- **Key Areas of Focus**: Antiviral drugs for HIV/AIDS, hepatitis B and C, influenza, and COVID-19
- **Public Listing**: Gilead is a member of the Nasdaq-100 and S&P 100 indices.

## Historical Milestones
- **1992**: Gilead went public.
- **2001**: Approval of Viread (tenofovir) for HIV treatment.
- **2002**: Shifted corporate strategy to focus exclusively on antiviral drugs.
- **2017**: Acquired Kite Pharma for $11.9 billion, marking its entry into the cell therapy market.

## Financial Performance
As of recent data, Gilead Sciences has a stock price of $92.37 with a market capitalization of approximately $115.12 billion. The stock has shown a slight increase of 0.36% recently[4].

Gilead continues to pursue ambitious goals in public health, focusing on improving drug accessibility and addressing healthcare disparities globally. The company is also committed to minimizing its environmental impact throughout its operations[3].

Citations:
[1] https://www.gilead.com
[2] https://en.wikipedia.org/wiki/Gilead_Sciences
[3] https://www.gilead.co.kr
[4] https://consent.yahoo.com/v2/collectConsent
[5] https://kr.linkedin.com/company/gilead-sciences
[6] https://x.com/gileadsciences